Preclinical Development of MucoCept
MucoCept 的临床前开发
基本信息
- 批准号:9121468
- 负责人:
- 金额:$ 95.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-06 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdvanced DevelopmentBacteriaBehavioral ResearchBiological AssayBiological Response Modifier TherapyBloodChronicClinicalClinical ResearchClinical TrialsCyanovirin-NCyclic GMPDetectionDevelopmentDevelopment PlansDiagnosticDoseEnzyme-Linked Immunosorbent AssayFemaleFormulationFreeze DryingFundingGoalsHIVHydrogen PeroxideLaboratoriesLifeLocal MicrobicidesMeasuresMethodologyMolecularOryctolagus cuniculusPeer ReviewPhase I Clinical TrialsPlacebosPreventionProcessProteinsRattusRecombinantsResearchTabletsTestingTissuesToxic effectUnited States Food and Drug AdministrationUnited States National Institutes of HealthVaginaWorkanalytical methodbasecGMP productioncell bankexpectationimprovedirritationmanufacturing processmeetingsmethod developmentmicrobicidenovel therapeuticspre-clinicalpreclinical safetypreclinical studyproduct developmentprogramsreproductive tractsafety studyscale upvaginal fluid
项目摘要
The overall goal of the Integrated Pre-Clinical & Clinical Program for HIV Microbicides and
Biomedical Prevention (IPCP)-MucoCept is to advance the development of Lactobacil/us jensenii
1153-1666 as a recombinant live biotherapeutic product (rLBP), leading to the testing of MucoCept
in a Phase 1 clinical trial
following the completion of this IPCP. MucoCept, a candidate microbicide developed by Osei, Inc.,
is a fast dissolving vaginal tablet containing the hydrogen peroxide-producing vaginal L. jensenii
strain that has been genetically modified to secrete a potent anti-HIV protein, modified
cyanovirin-N (mCV-N), thus greatly improving its capabilities as a topical microbicide.
Colonization of the vagina by L. jensenii 1153-1666 with continuous secretion of mCV-N is expected
to reduce HIV acquisition in the female genital tract.
After peer review, NIH DAIDS is now proposing to fund the remaining steps necessary for the
completion for the preclinical development and IND submission, with the expectation that subsequent
U01 applications will be submitted by the research team to fund the subsequent early clinical
studies, behavioral research and laboratory methodology necessary for the clinical trials.
The new scope of the project to be funded through a U01will conduct lnvestigational New Drug (IND)
enabling studies to comply with Food and Drug Administration (FDA) requirements for an IND for
MucoCept, and will optimize molecular-based diagnostics to measure colonization of by L jensenii
1153-1666 and secreted levels of mCV-N protein.
艾滋病毒杀微生物剂和艾滋病综合临床前和临床方案的总体目标
生物医学预防(IPCP)-MucoCept是为了促进Jensenii乳杆菌的发展
1153-1666作为重组活生物治疗产品(RLBP),导致检测MucoCept
在一期临床试验中
在完成这一IPCP之后。Osei,Inc.开发的候选杀菌剂MucoCept,
是一种快速溶解的阴道片,含有产生过氧化氢的阴道詹森氏杆菌
一种经过转基因的菌株,可以分泌一种有效的抗艾滋病毒蛋白,经过修改
氰韦林-N(MCV-N),从而极大地提高了其作为局部杀菌剂的能力。
持续分泌MCV-N的詹森乳杆菌1153-1666有望在阴道内定植
以减少艾滋病毒在女性生殖道的感染。
经过同行审查,NIH DAIDS现在提议为剩余的必要步骤提供资金
完成临床前开发和IND提交,预计后续
U01申请将由研究团队提交,以资助随后的早期临床
临床试验所需的研究、行为研究和实验室方法学。
通过U01资助的项目的新范围将进行新药研究(IND)
使研究符合食品和药物管理局(FDA)对IND的要求
MucoCept,并将优化基于分子的诊断来测量L Jensenii的定植
1153-1666,并分泌MCV-N蛋白。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG R COHEN其他文献
CRAIG R COHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG R COHEN', 18)}}的其他基金
University of California Launching Future Leaders in Global Health Research Training Program
加州大学推出全球健康研究未来领导者培训计划
- 批准号:
10879589 - 财政年份:2023
- 资助金额:
$ 95.01万 - 项目类别:
University of California Launching Future Leaders in Global Health Research Training Program
加州大学推出全球健康研究未来领导者培训计划
- 批准号:
10881124 - 财政年份:2023
- 资助金额:
$ 95.01万 - 项目类别:
Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa
在南非德班感染艾滋病毒高危女性中进行的 LACTIN-V(卷曲乳杆菌 CTV-05)的 2 期安慰剂对照随机试验
- 批准号:
10406532 - 财政年份:2021
- 资助金额:
$ 95.01万 - 项目类别:
University of California Global Health Institute Program for Fellows and Scholars
加州大学全球健康研究所研究员和学者计划
- 批准号:
10253430 - 财政年份:2021
- 资助金额:
$ 95.01万 - 项目类别:
Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa
在南非德班感染艾滋病毒高危女性中进行的 LACTIN-V(卷曲乳杆菌 CTV-05)的 2 期安慰剂对照随机试验
- 批准号:
10372975 - 财政年份:2019
- 资助金额:
$ 95.01万 - 项目类别:
Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa
在南非德班感染艾滋病毒高危女性中进行的 LACTIN-V(卷曲乳杆菌 CTV-05)的 2 期安慰剂对照随机试验
- 批准号:
10617632 - 财政年份:2019
- 资助金额:
$ 95.01万 - 项目类别:
Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa
在南非德班感染艾滋病毒高危女性中进行的 LACTIN-V(卷曲乳杆菌 CTV-05)的 2 期安慰剂对照随机试验
- 批准号:
10488446 - 财政年份:2019
- 资助金额:
$ 95.01万 - 项目类别:
Uwezo: Developing an Office of Sponsored Research in KEMRI with HIV Research Training
Uwezo:通过艾滋病毒研究培训在 KEMRI 中建立一个赞助研究办公室
- 批准号:
9277256 - 财政年份:2016
- 资助金额:
$ 95.01万 - 项目类别:
Agricultural intervention for food security and HIV healthoutcomes in Kenya
肯尼亚粮食安全和艾滋病毒健康结果的农业干预
- 批准号:
9064868 - 财政年份:2015
- 资助金额:
$ 95.01万 - 项目类别:
Agricultural intervention for food security and HIV healthoutcomes in Kenya
肯尼亚粮食安全和艾滋病毒健康结果的农业干预
- 批准号:
8922460 - 财政年份:2015
- 资助金额:
$ 95.01万 - 项目类别:
相似海外基金
Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria
针对抗生素耐药细菌的候选疫苗的高级开发
- 批准号:
10703335 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria
针对抗生素耐药细菌的候选疫苗的高级开发
- 批准号:
10343628 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
抗生素耐药细菌疫苗的先进开发
- 批准号:
10610281 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria
针对抗生素耐药细菌的候选疫苗的高级开发
- 批准号:
10819109 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
抗生素耐药细菌疫苗的先进开发
- 批准号:
10880209 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
抗生素耐药细菌疫苗的先进开发
- 批准号:
10471145 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
抗生素耐药细菌疫苗的先进开发
- 批准号:
10269630 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria
针对抗生素耐药细菌的候选疫苗的高级开发
- 批准号:
10269633 - 财政年份:2020
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria
抗生素耐药细菌治疗产品的高级开发
- 批准号:
10329726 - 财政年份:2019
- 资助金额:
$ 95.01万 - 项目类别:
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria
抗生素耐药细菌治疗产品的高级开发
- 批准号:
10708734 - 财政年份:2019
- 资助金额:
$ 95.01万 - 项目类别: